Diabetes News

Following a successful meeting in 2022, the Heart in Diabetes Conference is looking forward to hosting its seventh-annual meeting in Philadelphia in June.

Members of the U.S. Senate Committee on Health, Education, Labor and Pensions conducted a hearing on May 10 to investigate insulin affordability and what caused prices to increase during the past decade.

Adults with type 2 diabetes who switched from liraglutide to semaglutide therapy had greater reductions in HbA1c and body weight at 26 weeks than those who switched to dulaglutide, according to study data from researchers in Japan.

The FDA expanded an indication for the SGLT2 inhibitor dapagliflozin to reduce risk for CV death, HF hospitalization and urgent HF visits for adults with HF across the full range of ejection fraction, according to an industry press release.

In this video exclusive, Jonathan D. Leffert, MD, talks with Alyson K. Myers, MD, about disparities people with diabetes face and how those social determinants of health impact outcomes.

Kidney disease does not influence the benefits of the SGLT2 inhibitor empagliflozin on major HF events, even in patients at high renal risk, according to a new analysis of the EMPEROR-Pooled study.

Type 2 diabetes and atherosclerotic CVD risk varies considerably among Asian American subgroups and clinical trials assessing interventions must reflect the disparities within the Asian American population, researchers reported.

Fast-acting insulin aspart delivered through a hybrid closed-loop insulin delivery system provided similar glycemic outcomes as standard insulin aspart for young children with type 1 diabetes, according to study data.

SEATTLE — Adults with diabetes who used a GLP-1 receptor agonist after undergoing kidney transplantation had a decline in BMI and more stable measures of kidney function than those who did not use a GLP-1, according to a speaker.

SEATTLE — Providers treating people with type 2 diabetes should take a complication-centric approach for determining first-line pharmacotherapy, according to a consensus statement.